CRL vs INBX · rev $2.00B vs rev $1.3M
Charles River Laboratories (CRL) versus Inhibrx Biosciences, Inc. (INBX) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Inhibrx Biosciences, Inc. (INBX) is a biotechnology company listed on US.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
Latest reported INBX revenue for 2025-12-31 was $1.3M. Net income was -$140.1M. Revenue was up 550.0% from 2024-12-31 to 2025-12-31. INBX currently screens at market cap $1.28B.
CRL currently screens at market cap $7.78B. INBX currently screens at market cap $1.28B.
Not investment advice. Open the CRL and INBX stock pages for the full models.
Not investment advice.